ABLE members, Cipla and Kemwell Biopharma, have formed a joint venture to strengthen presence in the fast-growing biologics and biosimilars space. The announcement was made on March 2. 2026. The new venture aims to develop, manufacture and commercizlise biologics and biosimilars for global markets.

A new company will be incorporated in which Cipla will hold a 60 per cent stake while Kemwell will own the remaining 40 per cent.

Together they will initially invest up to ?10 crore in the new entity in proportion to their shareholding. At the time of incorporation, Cipla will subscribe to 6,000 equity shares of ?10 each at par, amounting to ?60,000.

The JV’s scope will include applying for and obtaining regulatory licences, as well as importing, exporting and outsourcing biologics-related activities, Cipla said in an exchange filing on BSE.

Kemwell is an Asia-based biologics contract development and manufacturing organisation (CDMO) that offers end-to-end services to global biopharma clients. Its Bengaluru facility, certified by the US Food and Drug Administration, houses 5,000-litre bioreactor capacity, sterile fill–finish lines and advanced development laboratories for protein therapeutics. The company supports both commercial manufacturing and R&D and clinical programmes for novel biologics and biosimilars.

Cipla said the transaction does not involve any related-party considerations and does not require any specific governmental or regulatory approvals at this stage.

A new company will be incorporated in which Cipla will hold a 60 per cent stake while Kemwell will own the remaining 40 per cent.